{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:05:50Z","timestamp":1783735550499,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Vaxart, Inc.","award":["R24AI120942"],"award-info":[{"award-number":["R24AI120942"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.vaccine.2019.04.069","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T08:26:56Z","timestamp":1556526416000},"page":"3146-3150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling"],"prefix":"10.1016","volume":"37","author":[{"given":"Emery G.","family":"Dora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannan L.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean N.","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.04.069_b0005","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrmicro2368","article-title":"Biology and pathogenesis of chikungunya virus","volume":"8","author":"Schwartz","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2019.04.069_b0010","unstructured":"Pan American Health Organization. Factsheet chikungunya; 2018. https:\/\/www.paho.org\/hq\/index.php?option=com_content&view=article&id=8303:2013-hoja-informativa-chikungunya&Itemid=40023&lang=en."},{"key":"10.1016\/j.vaccine.2019.04.069_b0015","unstructured":"WHO. Chikungunya \u2013 Mombasa, Kenya; Chikungunya \u2013 Italy; 2018. http:\/\/www.who.int\/csr\/don\/27-february-2018-chikungunya-kenya\/en\/, http:\/\/www.who.int\/csr\/don\/29-september-2017-chikungunya-italy\/en\/."},{"key":"10.1016\/j.vaccine.2019.04.069_b0020","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1016\/j.vaccine.2016.03.076","article-title":"Status of research and development of vaccines for chikungunya","volume":"34","author":"Smalley","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.069_b0025","doi-asserted-by":"crossref","first-page":"37295","DOI":"10.1038\/srep37295","article-title":"Systemic and mucosal immune responses following oral adenoviral delivery of influenza vaccine to the human intestine by radio controlled capsule","volume":"6","author":"Kim","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2019.04.069_b0030","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121077","article-title":"Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial","volume":"3","author":"Kim","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2019.04.069_b0035","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S1473-3099(15)00266-2","article-title":"High titer neutralizing antibodies to influenza following oral tablet immunization: a randomized, placebo-controlled trial","volume":"15","author":"Liebowitz","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.069_b0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1128\/CVI.00552-12","article-title":"An adenoviral-based vaccine with a dsRNA adjuvant protects against H5N1 avian influenza in oral delivery models in mice and ferrets","volume":"20","author":"Scallan","year":"2013","journal-title":"Clin Vacc Immunol"},{"key":"10.1016\/j.vaccine.2019.04.069_b0045","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.vaccine.2013.01.023","article-title":"Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans","volume":"31","author":"Peters","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.069_b0050","first-page":"64","article-title":"Limitations of current in vivo mouse models for the study of chikungunya virus pathogenesis","volume":"3","author":"Chan","year":"2015","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.vaccine.2019.04.069_b0055","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nm.4253","article-title":"A chikungunya fever vaccine utilizing an insect-specific virus platform","volume":"23","author":"Erasmus","year":"2017","journal-title":"Nat Med."},{"key":"10.1016\/j.vaccine.2019.04.069_b0060","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0264-410X(86)90003-4","article-title":"Development of an attenuated strain of chikungunya virus for use in vaccine production","volume":"4","author":"Levitt","year":"1986","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.069_b0065","doi-asserted-by":"crossref","first-page":"e0005637","DOI":"10.1371\/journal.pntd.0005637","article-title":"Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques","volume":"11","author":"Broeckel","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2019.04.069_b0070","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.12688\/f1000research.12461.1","article-title":"Chikungunya: vaccines and therapeutics","author":"Tharmarajah","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.vaccine.2019.04.069_b0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah3438","article-title":"Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis","volume":"9","author":"Miner","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2019.04.069_b0080","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.04.069_b0085","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1016\/j.vaccine.2013.05.086","article-title":"A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus","volume":"31","author":"Brandler","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.069_b0090","unstructured":"NIAID. Chikungunya virus vaccine trial in healthy adults; 2013. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01489358."},{"key":"10.1016\/j.vaccine.2019.04.069_b0095","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00253-015-7267-9","article-title":"Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production","volume":"100","author":"Tapia","year":"2016","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2019.04.069_b0100","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/vbz.2006.6.325","article-title":"Infectious clones of Chikungunya virus (La Reunion isolate) for vector competence studies","volume":"6","author":"Tsetsarkin","year":"2006","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2019.04.069_b0105","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02449-17","article-title":"Chikungunya virus strains show lineage-specific variations in virulence and cross-protective ability in murine and nonhuman primate models","volume":"9","author":"Langsjoen","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2019.04.069_b0110","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1525-0016(03)00180-1","article-title":"Systemic and mucosal antibody responses following retroductal gene transfer to the salivary gland","volume":"8","author":"Tucker","year":"2003","journal-title":"Mol Therapy"},{"key":"10.1016\/j.vaccine.2019.04.069_b0115","doi-asserted-by":"crossref","first-page":"e0003797","DOI":"10.1371\/journal.pntd.0003797","article-title":"IRES-containing VEEV vaccine protects cynomolgus macaques from IE venezuelan equine encephalitis virus aerosol challenge","volume":"9","author":"Rossi","year":"2015","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:32:01Z","timestamp":1759401121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19305572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":23,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0264410X19305572"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.069","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}